Imagify perflubutane regulatory update

FDA accepted for review an NDA from Acusphere for Imagify perflubutane as an ultrasound contrast agent to detect coronary artery disease (CAD). The PDUFA date is Feb. 28, 2009. Acusphere granted Nycom...